Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (111-120 of 635) with videos related to

Pageof 64
Sort By:
Clinics (Sao Paulo, Brazil)|October 4, 2018
Academic health centers: integration of clinical research with healthcare and education. Comments on a workshopRoberto Jun Arai, Irene de Lourdes Noronha, José Carlos Nicolau, et al.
The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS TrialTaha Sen, Jingwei Li, Brendon L Neuen, et al.
JAMA Cardiology|November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker StudyDaniel Lindholm, Stefan K James, Katja Gabrysch, et al.
Diabetes Care|June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.
Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
JACC. Cardiovascular Interventions|November 19, 2013
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)Hemal Gada, Ajay J Kirtane, William Newman, et al.
The American Journal of Cardiology|October 29, 2005
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromesSunil V Rao, Kristi O'Grady, Karen S Pieper, et al.
Circulation|October 7, 2008
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus DocumentsDeepak L Bhatt, James Scheiman, Neena S Abraham, et al.
Clinical Cardiology|February 4, 2010
Influence of clinical trial participation on subsequent antithrombin useBimal R Shah, Eric D Peterson, Anita Y Chen, et al.
Pageof 64

Showing results (111-120 of 635) with videos related to

Sort By:
Pageof 64
Clinics (Sao Paulo, Brazil)|October 4, 2018
Academic health centers: integration of clinical research with healthcare and education. Comments on a workshopRoberto Jun Arai, Irene de Lourdes Noronha, José Carlos Nicolau, et al.
The Lancet. Diabetes & Endocrinology|June 26, 2018
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialsVlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS TrialTaha Sen, Jingwei Li, Brendon L Neuen, et al.
JAMA Cardiology|November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker StudyDaniel Lindholm, Stefan K James, Katja Gabrysch, et al.
Diabetes Care|June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.
Circulation|November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
JACC. Cardiovascular Interventions|November 19, 2013
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)Hemal Gada, Ajay J Kirtane, William Newman, et al.
The American Journal of Cardiology|October 29, 2005
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromesSunil V Rao, Kristi O'Grady, Karen S Pieper, et al.
Circulation|October 7, 2008
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus DocumentsDeepak L Bhatt, James Scheiman, Neena S Abraham, et al.
Clinical Cardiology|February 4, 2010
Influence of clinical trial participation on subsequent antithrombin useBimal R Shah, Eric D Peterson, Anita Y Chen, et al.
Pageof 64